NO20011409L - Farmasöytiske midler for behandling av Parkinsonssykdom, ADHD og mikroadenomer - Google Patents

Farmasöytiske midler for behandling av Parkinsonssykdom, ADHD og mikroadenomer

Info

Publication number
NO20011409L
NO20011409L NO20011409A NO20011409A NO20011409L NO 20011409 L NO20011409 L NO 20011409L NO 20011409 A NO20011409 A NO 20011409A NO 20011409 A NO20011409 A NO 20011409A NO 20011409 L NO20011409 L NO 20011409L
Authority
NO
Norway
Prior art keywords
microadenomas
adhd
parkinson
pharmaceuticals
disease
Prior art date
Application number
NO20011409A
Other languages
English (en)
Norwegian (no)
Other versions
NO20011409D0 (no
Inventor
Elisa Rose Jackson
Stafford Mclean
Stevin Howard Zorn
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20011409D0 publication Critical patent/NO20011409D0/no
Publication of NO20011409L publication Critical patent/NO20011409L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20011409A 1998-09-21 2001-03-20 Farmasöytiske midler for behandling av Parkinsonssykdom, ADHD og mikroadenomer NO20011409L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10119198P 1998-09-21 1998-09-21
US10386898P 1998-10-12 1998-10-12
PCT/IB1999/001503 WO2000016777A1 (fr) 1998-09-21 1999-09-03 Substances a usage pharmaceutique destinees au traitement de la maladie de parkinson, de l'hyperactifvite avec deficit de l'attention et du microadenome

Publications (2)

Publication Number Publication Date
NO20011409D0 NO20011409D0 (no) 2001-03-20
NO20011409L true NO20011409L (no) 2001-03-28

Family

ID=26798000

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011409A NO20011409L (no) 1998-09-21 2001-03-20 Farmasöytiske midler for behandling av Parkinsonssykdom, ADHD og mikroadenomer

Country Status (38)

Country Link
US (2) US6300329B1 (fr)
EP (1) EP1115402A1 (fr)
JP (1) JP2002526448A (fr)
KR (3) KR20030088512A (fr)
CN (1) CN1319013A (fr)
AP (1) AP1456A (fr)
AR (1) AR029739A1 (fr)
AU (1) AU760230B2 (fr)
BG (1) BG105445A (fr)
BR (1) BR9913975A (fr)
CA (1) CA2344670A1 (fr)
CO (1) CO5140075A1 (fr)
CZ (1) CZ20011006A3 (fr)
DZ (1) DZ2894A1 (fr)
EA (2) EA200100204A1 (fr)
EE (1) EE200100179A (fr)
GE (1) GEP20033081B (fr)
GT (1) GT199900154A (fr)
HN (1) HN1999000146A (fr)
HR (1) HRP20010209A2 (fr)
HU (1) HUP0103691A3 (fr)
ID (1) ID28028A (fr)
IL (2) IL164839A0 (fr)
IS (1) IS5852A (fr)
MA (1) MA26690A1 (fr)
MY (1) MY127939A (fr)
NO (1) NO20011409L (fr)
NZ (1) NZ509855A (fr)
OA (1) OA11653A (fr)
PA (1) PA8482001A1 (fr)
PE (1) PE20001084A1 (fr)
PL (1) PL346904A1 (fr)
SK (1) SK3592001A3 (fr)
TN (1) TNSN99177A1 (fr)
TR (2) TR200402083T2 (fr)
TW (1) TW518225B (fr)
WO (1) WO2000016777A1 (fr)
YU (1) YU21701A (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
WO2001068104A1 (fr) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Composes servant a traiter des troubles psychiatriques ou des troubles provoques par la consommation abusive de substances psychoactives
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
WO2002102988A2 (fr) * 2001-06-18 2002-12-27 Psychiatric Genomics, Inc. Procede de differenciation de cellule souche neuronale par le biais d'agonistes vis-a-vis du recepteur 5ht-1a
US20030036555A1 (en) * 2001-08-03 2003-02-20 Boehringer Ingelheim Pharma Kg Pramipexole for the treatment of ADHD
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
WO2005122767A1 (fr) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, notamment de l'uridine, utilisees dans des traitements sur des patients atteints de troubles bipolaires
US7947661B2 (en) * 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
PE20070523A1 (es) 2005-09-12 2007-06-28 Wyeth Corp Formulacion de liberacion sostenida del glucuronato de (8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008083442A1 (fr) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Procédé pour la formulation de médicaments mixtes contre tdah
CN101318020B (zh) * 2007-06-06 2011-09-28 四川科瑞德制药有限公司 抗焦虑或/和抗抑郁的药物组合物及用途
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9463186B2 (en) 2013-04-15 2016-10-11 Northwestern University Treatment for dopaminergic disorders
CN104892589A (zh) 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
US11426366B2 (en) 2015-05-15 2022-08-30 Arizona Board Of Regents On Behalf Of The Universsity Of Arizona Compositions and methods for treating motor disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008148A1 (fr) * 1989-01-23 1990-07-26 Pfizer Inc. Agents anxiolytiques bis-aza-bicycliques
WO1992000075A1 (fr) * 1990-06-29 1992-01-09 Pfizer Inc. Derives de pyridopyrazine utilises dans le traitement de l'abus et de la dependance de substances
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
GB9408084D0 (en) * 1994-04-23 1994-06-15 Boots Co Plc Medical treatment
WO1995034555A1 (fr) * 1994-06-14 1995-12-21 Pfizer Inc. Derives de la benzimidazolone a activite dopaminergique centrale
US5877183A (en) * 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.

Also Published As

Publication number Publication date
TR200101357T2 (tr) 2001-08-21
IL164839A0 (en) 2005-12-18
TNSN99177A1 (fr) 2005-11-10
HRP20010209A2 (en) 2002-04-30
KR20030088512A (ko) 2003-11-19
EA200100204A1 (ru) 2001-08-27
PL346904A1 (en) 2002-03-11
BR9913975A (pt) 2001-06-19
CN1319013A (zh) 2001-10-24
NO20011409D0 (no) 2001-03-20
US20010034347A1 (en) 2001-10-25
WO2000016777A1 (fr) 2000-03-30
PA8482001A1 (es) 2000-05-24
KR100468340B1 (ko) 2005-01-27
BG105445A (en) 2001-12-29
EE200100179A (et) 2002-10-15
EP1115402A1 (fr) 2001-07-18
HUP0103691A3 (en) 2003-01-28
ID28028A (id) 2001-05-03
US6300329B1 (en) 2001-10-09
IS5852A (is) 2001-02-20
YU21701A (sh) 2004-07-15
US6608064B2 (en) 2003-08-19
PE20001084A1 (es) 2000-10-18
TW518225B (en) 2003-01-21
AU5383199A (en) 2000-04-10
MA26690A1 (fr) 2004-12-20
KR20040054752A (ko) 2004-06-25
GEP20033081B (en) 2003-10-27
KR20010075222A (ko) 2001-08-09
AR029739A1 (es) 2003-07-16
HN1999000146A (es) 2000-11-11
DZ2894A1 (fr) 2003-12-15
CO5140075A1 (es) 2002-03-22
GT199900154A (es) 2001-03-06
SK3592001A3 (en) 2001-12-03
TR200402083T2 (tr) 2004-10-21
IL141507A0 (en) 2002-03-10
EA200301063A1 (ru) 2004-12-30
CZ20011006A3 (cs) 2001-09-12
JP2002526448A (ja) 2002-08-20
NZ509855A (en) 2003-04-29
CA2344670A1 (fr) 2000-03-30
AU760230B2 (en) 2003-05-08
HUP0103691A2 (hu) 2002-02-28
AP1456A (en) 2005-09-30
OA11653A (en) 2004-12-08
AP2001002102A0 (en) 2001-03-31
MY127939A (en) 2007-01-31

Similar Documents

Publication Publication Date Title
NO20011409D0 (no) Farmasøytiske midler for behandling av Parkinsonssykdom, ADHD og mikroadenomer
CY2018020I2 (el) Θεραπεια της νοσου ρομρε
NO20063000L (no) Kombinasjon og farmasøytisk blanding for behandling av diabetes samt anvendelse derav.
NO20004098D0 (no) FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser
FI20000720A7 (fi) Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi
WO1999048482A3 (fr) Smilagenine et anzurogenine d et leur utilisation
NO20006630D0 (no) Farmasöytisk sammensetning for behandlingen av diabetes
ATE438630T1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
NO986089D0 (no) Metoder og preparater for behandling av tumorer, tumorrelaterte sykdommer o
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
NO20015542L (no) Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
NO20012963D0 (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
DK1202996T3 (da) Titanforbindelser, fremstilling og anvendelse heraf
ITRM930291A0 (it) Procedimento per la preparazione di biopolimeri iodurati con attivita'disinfettante e cicatrizzante, e biopolimeri iodurati cosi' ottenuti.
NO20001909D0 (no) Fremgangsmõte og anlegg for fremstilling av 1,2-dikloretan
DE69604071D1 (de) Oxazolidinone derivate, ihre herstellung und ihre therapeutische verwendung
HUP0105111A3 (en) 2,5-substituted benzolsulfonylureas and thioureas, methods for the production thereof, use thereof and pharmaceutical preparations containing the same
NO20012612L (no) Isonipecotamider for behandlingen av integrin-formidlede sykdommer
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
IT1320401B1 (it) Procedimento per la fabbricazione di componenti di un'ossatura ecomponenti di ossatura.
ZA200102029B (en) Pharmaceutical agents for the treatment of Parkinson's disease, ADHD and microadenomas.
NO983492D0 (no) 2,3-disubstituerte cyklopentanderivater, fremgangsmÕte for fremstilling derav, og medisinsk anvendelse derav
EE200100062A (et) Uued 2,3,3a,4,9,9a-heksahüdro-8-hydroxy-1H-bens(f)indoolid, meetodid nende valmistamiseks ja nende kasutamine ravimitena
NO970190D0 (no) Preparat til behandling av Parkinsons sykdom

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application